Similar articles

• Bexarotene monotherapy for epidermotropic CD8+ CTCL.

  Kamstrup M, Gniadecki R. Kamstrup M, et al. Dermatol Clin. 2008 Jan;26 Suppl 1:45-7. Dermatol Clin. 2008. PMID: 18405187 No abstract available.
• Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.

  French LE, Shapiro M, Junkins-Hopkins JM, Vittorio CC, Rook AH. French LE, et al. J Am Acad Dermatol. 2001 Dec;45(6):914-8. doi: 10.1067/mjd.2001.117519. J Am Acad Dermatol. 2001. PMID: 11712039
• Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.

  Kreuter A, Altmeyer P, Gambichler T. Kreuter A, et al. Acta Derm Venereol. 2006;86(3):274-5. doi: 10.2340/00015555-0059. Acta Derm Venereol. 2006. PMID: 16710601 No abstract available.
• Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).

  Guitart J. Guitart J. Semin Oncol. 2006 Feb;33(1 Suppl 3):S17-20. doi: 10.1053/j.seminoncol.2005.12.018. Semin Oncol. 2006. PMID: 16516671 Review.
• Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.

  Martin AG. Martin AG. J Drugs Dermatol. 2003 Apr;2(2):155-67. J Drugs Dermatol. 2003. PMID: 12852367 Review.